Cargando…
Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives
Radical cystectomy is the primary treatment for muscle-invasive bladder cancer; however, approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which results in dismal prognosis. Therefore, systemic treatment is important to improve the prognosis of muscle-invasive bla...
Autores principales: | Kim, In-Ho, Lee, Hyo-Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268978/ https://www.ncbi.nlm.nih.gov/pubmed/34281253 http://dx.doi.org/10.3390/ijms22137201 |
Ejemplares similares
-
Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020) -
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2023) -
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies
por: Kim, Kyung Hwan, et al.
Publicado: (2023) -
Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020) -
Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives
por: Fan, Xinxiang, et al.
Publicado: (2023)